Hanyu Pharmaceutical: The enrollment of all subjects in the Phase III clinical trial for the weight loss indication of Semaglutide Injection has been completed.

GoldenOctober2024

2025-06-12 04:21:14

On June 12, Hanyu Pharmaceutical said on the interactive platform that the company’s semaglutide injection was declared for marketing in accordance with Class 2.2, of which the bariatric indication had completed the enrollment of all subjects in the phase III clinical trial in January this year, and was currently in the follow-up stage, and the project had entered the dose maintenance period. After the completion of the Phase III clinical trial in the future, the Company will submit a marketing application after collating and improving the clinical trial data in accordance with relevant regulatory requirements.

View Original

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.

Comment

0/400

No comments